Antifungal, cytotoxic, and immunomodulatory properties of tea tree oil and its derivative components: Potential role in management of oral candidosis in cancer patients

Frontiers in Microbiology

Volumn 3, Issue JUN, 2012, Pages

  Ramage, Gordon ^a   Milligan, Steven ^a   Lappin, David F ^a   Sherry, Leighann ^a   Sweeney, Petrina ^a   Williams, Craig ^b   Bagg, Jeremy ^a   Culshaw, Shauna ^a  

^a GLASGOW DENTAL HOSPITAL AND SCHOOL   (United Kingdom)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

Author keywords

Antifungal agent; Oral cancer; Oral candidosis; Tea tree oil; Terpinen 4 ol

Indexed keywords

EID: 84875764793     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2012.00220     Document Type: Article

References (57)

1. Akins, R. A. (2005). An update on antifungal targets and mechanisms of resistance in Candida albicans. Med. Mycol. 43,285-318.
2. Bagg, J., Jackson, M. S., Petrina Sweeney, M., Ramage, G., and Davies, A. N. (2006). Susceptibility to Melaleuca alternifolia (tea tree) oil of yeasts isolated from the mouths of patients with advanced cancer. Oral Oncol. 42,487-492.
3. Bagg, J., Sweeney, M. P., Lewis, M. A., Jackson, M. S., Coleman, D., Al, M. A., Baxter, W., McEndrick, S., and McHugh, S. (2003). High prevalence of non-albicans yeasts and detection of anti-fungal resistance in the oral flora of patients with advanced cancer. Palliat. Med. 17, 477-481.
4. Bozzuto, G., Colone, M., Toccacieli, L., Stringaro, A., and Molinari, A. (2011). Tea tree oil might combat melanoma. Planta Med. 77, 54-56.
5. Brand, C., Grimbaldeston, M. A., Gamble, J. R., Drew, J., Finlay-Jones, J. J., and Hart, P. H. (2002a). Tea tree oil reduces the swelling associated with the efferent phase of a contact hypersensitivity response. Inflamm. Res. 51,236-244.
6. Brand, C., Townley, S. L., Finlay-Jones, J. J., and Hart, P. H. (2002b). Tea tree oil reduces histamine-induced oedema in murine ears. Inflamm. Res. 51,283-289.
7. Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Tanabe, K., Niimi, M., and Monk, B.C. (2007). Candida albicans drug resistance another way to cope with stress. Microbiology 153, 3211-3217.
8. Carson, C. F., Ashton, L., Dry, L., Smith, D. W., and Riley, T. V. (2001). Melaleuca alternifolia (tea tree) oil gel (6%) for the treatment of recurrent herpes labialis. J. Antimi-crob. Chemother. 48, 450-451.
9. Carson, C. F., Hammer, K. A., and Riley, T. V. (2006). Melaleuca alternifolia (tea tree) oil: a review of antimicrobial and other medicinal properties. Clin. Microbiol. Rev. 19, 50-62.
10. Casalinuovo, I. A., Di Francesco, P., and Garaci, E. (2004). Fluconazole resistance in Candida albicans: a review of mechanisms. Eur. Rev. Med. Pharmacol. Sci. 8, 69-77.
11. Clinical Laboratory Standards Institute. (2008). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast, Approved Standard-3rd Edn, CLSI documentM27-A3. Wayne: CLSI.
12. Davies, A. N., Brailsford, S., Broadley, K., and Beighton, D. (2002). Oral yeast carriage in patients with advanced cancer. Oral Microbiol. Immunol. 17, 79-84.
13. Davies, A. N., Brailsford, S. R., and Beighton, D. (2006). Oral candidosis in patients with advanced cancer. Oral Oncol. 42, 698-702.
14. de Groot, A. C., and Weyland, J. W. (1992). Systemic contact dermatitis from tea tree oil. Contact Derm. 27, 279-280.
15. d'Enfert, C. (2006). Biofilms and their role in the resistance of pathogenic Candida to antifungal agents. Curr. Drug Targets 7, 465-470.
16. Dongari-Bagtzoglou, A., and Kashleva, H. (2003). Candida albicans triggers interleukin-8 secretion by oral epithelial cells. Microb. Pathog. 34, 169-177.
17. Dreizen, S. (1990). Oral complications of cancer therapies. Description and incidence of oral complications. NCI Monogr. 11-15.
18. Erlandsen, S. L., Kristich, C. J., Dunny, G. M., and Wells, C. L. (2004). High-resolution visualization of the microbial glycocalyx with low-voltage scanning electron microscopy: dependence on cationic dyes. J. Histochem. Cytochem. 52, 1427-1435.
19. Ganguly, S., and Mitchell, A. P. (2011). Mucosal biofilms of Candida albicans. Curr. Opin. Microbiol. 14, 380-385.
20. Garozzo, A., Timpanaro, R., Stivala, A., Bisignano, G., and Castro, A. (2011). Activity of Melaleuca alternifolia (tea tree) oil on influenza virus A/PR/8: study on the mechanism of action. Antiviral Res. 89, 83-88.
21. Golab, M., and Skwarlo-Sonta, K. (2007). Mechanisms involved in the anti-inflammatory action of inhaled tea tree oil in mice. Exp. Biol. Med. (Maywood) 232,420-426.
22. Hammer, K. A., Carson, C. F., and Riley, T. V. (2003a). Antifungal activity of the components of Melaleuca alternifolia (tea tree) oil. J. Appl. Microbiol. 95, 853-860.
23. Hammer, K. A., Dry, L., Johnson, M., Michalak, E. M., Carson, C. F., and Riley, T. V. (2003b). Susceptibility of oral bacteria to Melaleuca alternifolia (tea tree) oil in vitro. Oral Microbiol. Immunol. 18, 389-392.
24. Hammer, K. A., Carson, C. F., and Riley, T. V. (2004). Antifungal effects of Melaleuca alternifolia (tea tree) oil and its components on Candida albicans, Candida glabrata and Saccharomyces cere-visiae. J. Antimicrob. Chemother. 53, 1081-1085.
25. Hammer, K. A., Carson, C. F., and Riley, T. V. (2012). Effects of Melaleuca alternifolia (tea tree) essential oil and the major monoter-pene component terpinen-4-ol on the development of single-and multistep antibiotic resistance and antimicrobial susceptibility. Antimicrob. Agents Chemother. 56, 909-915.
26. Hammer, K. A., Carson, C. F., Riley, T.V., and Nielsen, J. B. (2006). A review of the toxicity of Melaleuca alternifolia (tea tree) oil. Food Chem. Toxicol. 44, 616-625.
27. Hart, P. H., Brand, C., Carson, C. F., Riley, T. V., Prager, R. H., and Finlay-Jones, J. J. (2000). Terpinen-4-ol, the main component of the essential oil of Melaleuca alternifolia (tea tree oil), suppresses inflammatory mediator production by activated human monocytes. Inflamm. Res. 49, 619-626.
28. Hartford, O., and Zug, K. A. (2005). Tea tree oil. Cutis 76, 178-180.
29. Hayes, A. J., Leach, D. N., and Markham, J. L. (1997). In vitro cytotoxic-ity of Australian tea tree oil using human cell lines. J. Essent. Oil Res. 9,572-582.
30. Khalil, Z., Pearce, A. L., Satkunanathan, N., Storer, E., Finlay-Jones, J. J., and Hart, P. H. (2004). Regulation of wheal and flare by tea tree oil: complementary human and rodent studies. J. Invest. Dermatol. 123, 683-690.
31. Knight, T. E., and Hausen,B.M. (1994). Melaleuca oil (tea tree oil) dermatitis. J. Am. Acad. Dermatol. 30, 423-427.
32. Koh, K. J., Pearce, A. L., Marsh-man, G., Finlay-Jones, J. J., and Hart, P. H. (2002). Tea tree oil reduces histamine-induced skin inflammation. Br. J. Dermatol. 147, 1212-1217.
33. Kuhn, D. M., and Ghannoum, M. A. (2004). Candida biofilms: antifungal resistance and emerging therapeutic options. Curr. Opin. Investig. Drugs 5, 186-197.
34. Kwiecinski, J., Eick, S., and Wojcik, K. (2009). Effects of tea tree (Melaleuca alternifolia) oil on Staphylococcus aureus in biofilms and stationary growth phase. Int. J. Antimicrob. Agents 33,343-347.
35. Lamfon, H., Porter, S. R., McCullough, M., and Pratten, J. (2004). Susceptibility of Candida albicans biofilms grown in a constant depth film fer-mentor to chlorhexidine, flucona-zole and miconazole: a longitudinal study. J. Antimicrob. Chemother. 53, 383-385.
36. Mondello, F., De Bernardis, F., Giro-lamo, A., Cassone, A., and Salva-tore, G. (2006). In vivo activity of terpinen-4-ol, the main bioactive component of Melaleuca alternifolia Cheel (tea tree) oil against azole-susceptible and -resistant human pathogenic Candida species. BMC Infect. Dis. 6,158. doi:10.1186/1471-2334-6-158
37. Mondello, F., De Bernardis, F., Giro-lamo, A., Salvatore, G., and Cassone, A. (2003). In vitro and in vivo activity of tea tree oil against azole-susceptible and resistant human pathogenic yeasts. J. Antimicrob. Chemother. 51, 1223-1229.
38. Mowat, E., Butcher, J., Lang, S., Williams, C., and Ramage, G. (2007). Development of a simple model for studying the effects of antifungal agents on multicel-lular communities of Aspergillus fumigatus. J. Med. Microbiol. 56, 1205-1212.
39. Mozelsio, N. B., Harris, K. E., McGrath, K. G., and Grammer, L. C. (2003). Immediate systemic hypersensitiv-ity reaction associated with topical application of Australian tea tree oil. Allergy Asthma Proc. 24, 73-75.
40. Niimi, M., Firth, N. A., and Cannon, R. D. (2010). Antifungal drug resistance of oral fungi. Odontology 98, 15-25.
41. Pearce, A. L., Finlay-Jones, J. J., and Hart, P. H. (2005). Reduction of nickel-induced contact hypersensi-tivity reactions by topical tea tree oil in humans. Inflamm. Res. 54,22-30.
42. Ramage, G., Saville, S. P., Thomas, D. P., and Lopez-Ribot, J. L. (2005). Candida biofilms: an update. Eukaryot. Cell 4, 633-638.
43. Ramage, G., Vande Walle, K., Wickes, B. L., and Lopez-Ribot, J. L. (2001). Standardized method for in vitro antifungal susceptibility test ing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45, 2475-2479.
44. Ramage, G., Zalewska, A., Cameron, D., Sherry, L., Murray, C., Finnegan, M. B., Lowey, Z., and Jagger, D. C. (2012). A comparative in vitro study of two denture cleaning tech niques as an effective strategy for inhibiting Candida albicans biofilms on denture surfaces and inducing inflammation. J. Prosthodont. doi: 10.1111/j.1532-849X.2012.00865.x
45. Rutherford, T., Nixon, R., Tam, M., and Tate,B. (2007). Allergy to tea tree oil: retrospective review of 41 cases with positive patch tests over 4.5 years. Australas. J. Dermatol. 48, 83-87.
46. Sanglard, D., and Odds, F. C. (2002). Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet. Infect. Dis. 2, 73-85.
47. Sherry, L., Jose, A., Murray, C., Williams, C., Jones, B., Milling-ton, O., Bagg, J., and Ramage, G. (2012). Carbohydrate derived ful-vic acid: an in vitro investigation of a novel membrane active antiseptic agent against Candida albicans biofilms. Front. Microbiol. 3:116. doi:10.3389/fmicb.2012.00116
48. Silva, S., Henriques, M., Martins, A., Oliveira, R., Williams, D., and Azeredo, J. (2009). Biofilms of non-Candida albicans Candida species: quantification, structure and matrix composition. Med. Mycol. 47, 681-689.
49. Soderberg, T. A., Johansson, A., and Gref, R. (1996). Toxic effects of some conifer resin acids and tea tree oil on human epithelial and fibroblast cells. Toxicology 107, 99-109.
50. Soukoulis,S., andHirsch,R. (2004). The effects of a tea tree oil-containing gel on plaque and chronic gingivitis. Aust. Dent. J. 49, 78-83.
51. Straede, A., Corran, A., Bundy, J., and Heinisch, J. J. (2007). The effect of tea tree oil and antifungal agents on a reporter for yeast cell integrity signalling. Yeast 24, 321-334.
52. Sweeney, M. P., and Bagg, J. (2000). The mouth and palliative care. Am. J. Hosp. Palliat. Care 17, 118-124.
53. Sweeney, M. P., Bagg, J., Baxter, W P., and Aitchison, T. C. (1998). Oral disease in terminally ill cancer patients with xerostomia. Oral Oncol. 34, 123-126.
54. Terzi,V., Morcia, C.,Faccioli, P., Vale, G., Tacconi, G., and Malnati, M. (2007). In vitro antifungal activity of the tea tree (Melaleuca alternifolia) essential oil and its major components against plant pathogens. Lett. Appl. Microbiol. 44, 613-618.
55. Thompson, G., Blackwood, B., McMul-lan, R., Alderdice, F. A., Trinder, T. J., Lavery, G. G., and McAuley, D. F. (2008). A randomized controlled trial of tea tree oil (5%) body wash versus standard body wash to prevent colonization with methicillin-resistant Staphylo coccus aureus (MRSA) in critically ill adults: research protocol. BMC Infect. Dis. 8, 161. doi:10.1186/1471-2334-8-161
56. Williams, D. W., Kuriyama, T., Silva, S., Malic, S., and Lewis, M. A. (2011). Candida biofilms and oral candidosis: treatment and prevention. Periodontol. 2000 55, 250-265.
57. Wingard, J. R. (1990). Oral complications of cancer therapies. Infectious and non-infectious systemic consequences. NCIMonogr. 9, 21-26.